Australia funds Abbott's psoriasis drug, while Raptiva dropped
This article was originally published in Scrip
Executive Summary
The Australian state-funded pharmaceutical benefits scheme (PBS) is to fund Abbott Laboratories' Humira (adalimumab) for severe chronic plaque psoriasis as an alternative treatment to other TNF-alfa inhibitors already funded for this condition.